|
MX2009006346A
|
|
8-ethinylxanthine derivatives as selective a2a receptor antagonists.
|
|
EP2058306A1
|
|
Heteroaryl-substituted 2-pyridinyl-methylamine derivatives
|
|
CA2651679A1
|
|
Pharmaceutical composition with synergistic anticonvulsant effect
|
|
BRPI0712865A2
|
|
stabilized pharmaceutical compositions comprising fesoterodine
|
|
UA94107C2
|
|
Stabilized pharmaceutical composition comprising fesoterodine
|
|
CN101484152A
|
|
Therapeutic combination for painful medical conditions
|
|
MX2008015736A
|
|
Stabilized pharmaceutical compositions comprising fesoterodine.
|
|
BRPI0712494A2
|
|
therapeutic combination for painful medical conditions
|
|
TW200817315A
|
|
Entacapone-derivatives
|
|
EP1987815A1
|
|
Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
|
|
EP1972628A1
|
|
Indolizines and aza-analog derivatives thereof as CNS active compounds
|
|
EP1939197A1
|
|
8-ethinylxanthine derivatives as selective A2A receptor antagonists
|
|
IL179540D0
|
|
Novel use of peptide compounds for treating pain in trigeminal neuralgia
|
|
IL179528D0
|
|
Novel use of peptide compounds for treating amyotrophic lateral sclerosis
|
|
EP1925314A1
|
|
Pharmaceutical composition with synergistic anticonvulsant effect
|
|
EP1920780A1
|
|
Peptide compounds for the treatment of hyperexcitability disorders
|
|
KR20080038408A
|
|
Novel use of peptide compounds for treating muscle pain
|
|
US2008227995A1
|
|
Process of Sulfonating 4-Aminobenzonitriles
|
|
EP1873527A1
|
|
Method for identifying CRMP modulators
|
|
CN101043882A
|
|
Use of peptide compounds for treating bone cancer pain, chemotherapy- and nucleoside-induced pain
|
